anti-Müllerian激素在人类颗粒细胞中的调控与信号传导:与多囊卵巢综合征的相关性
该研究探讨多囊卵巢综合征(PCOS)中抗苗勒管激素(AMH)水平不下降的机制及其对卵泡发育的影响。研究发现,相当于PCOS水平的高雄激素暴露阻止了AMH下降,并与AMH-SMAD信号传导失调相关,导致卵泡发育停滞。PCOS颗粒细胞对持续升高的AMH反应性降低,呈现「AMH抵抗」现象。
要点
- 高雄激素水平阻止颗粒细胞AMH下降,与PCOS卵泡发育停滞相关。
- PCOS颗粒细胞中AMH-SMAD信号通路发生适应性改变,对AMH反应性降低。
- AMH可能通过雄激素直接作用或转化为雌二醇经ERα上调间接调控。
核心结论
- 相当于PCOS水平的高雄激素暴露阻止了AMH下降,并与AMH-SMAD信号传导失调相关,导致PCOS卵泡发育停滞。
- PCOS颗粒细胞对持续升高的AMH反应性降低,表现为SMAD信号通路适应性改变和AMHRII表达降低,提示「AMH抵抗」。
研究设计与样本
- 研究使用人KGN颗粒细胞系(对应小窦卵泡未成熟颗粒细胞)与不同剂量雄激素培养,检测对AMH产生的影响。
- 研究还使用来自正常卵巢、多囊卵巢形态(PCOM)和PCOS女性的黄素化颗粒细胞(hGLC),探究AMH对基因表达和SMAD信号的剂量相关效应。
- KGN-GC还长期暴露于不同剂量AMH以评估对细胞增殖和活力的影响。
主要发现
- 睾酮在10^-9至10^-7 M浓度降低KGN-GC分泌的AMH蛋白(P<0.05;P<0.005,多重未校正比较Fisher最小显著差法),但在相当于高雄激素血症水平时AMH水平无变化。
- 5α-二氢睾酮(5α-DHT)对培养基中AMH蛋白分泌产生显著的剂量相关增加(P=0.022,ANOVA)。
- 增加ERα:ERβ mRNA比值产生相应的AMH mRNA表达增加(P=0.015,双因素ANOVA)。
- AMH增加PCOM女性hGLC中芳香化酶mRNA水平(P<0.05,单因素ANOVA)和FSHR mRNA水平(P<0.0001,单因素ANOVA),但在正常细胞或PCOS细胞中无此效应(正常n=7,PCOM n=5,PCOS n=4)。
- 与排卵卵巢hGLC相反,PCOS中AMH降低刺激性pSMAD-1/5/8和SMAD-4的蛋白水平(细胞内容物)但增加抑制性SMAD-6和-7(P<0.05,正常n=6,PCOS n=3)。
临床怎么用
- 研究提示PCOS中高雄激素水平可能通过阻止AMH下降参与卵泡发育停滞的病理机制。
- PCOS颗粒细胞呈现「AMH抵抗」现象,可能与SMAD信号通路适应性改变和AMHRII低表达相关。
- 这些发现为理解PCOS无排卵性不孕的机制提供了新视角,但尚需进一步研究转化为临床实践。
局限性
- 来自接受IVF女性的黄素化颗粒细胞AMH/AMHRII表达相对较低但继续显示与卵巢形态相关的反应。
- 为补偿上述局限,研究还使用了KGN细胞系,该细胞系已被表征为接近未成熟颗粒细胞的发育阶段。
- 氟他胺对睾酮效应缺乏影响本身不足以证明对AMH的效应是通过转化为雌激素介导的,芳香化酶抑制剂或雌激素特异性抑制剂的效应应被测试。
- 氟他胺的效应仅在睾酮上测试,未在DHT上测试。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What prevents the fall in anti-Müllerian hormone (AMH) levels in polycystic ovary syndrome (PCOS) and what are the consequences of this for follicle progression in these ovaries? SUMMARY ANSWER: Exposure of granulosa cells (GCs) to high levels of androgens, equivalent to that found in PCOS, prevented the fall in AMH and was associated with dysregulated AMH-SMAD signalling leading to stalled follicle progression in PCOS. WHAT IS KNOWN ALREADY: In normal ovaries, AMH exerts an inhibitory role on antral follicle development and a fall in AMH levels is a prerequisite for ovulation. Levels of AMH are high in PCOS, contributing to the dysregulated follicle growth that is a common cause of anovulatory infertility in these women. STUDY DESIGN, SIZE, DURATION: Human KGN-GC (the cell line that corresponds to immature GC from smaller antral follicles (AF)) were cultured with a range of doses of various androgens to determine the effects on AMH production. KGN-GC were also treated with PHTPP (an oestrogen receptor β (ERβ) antagonist) to examine the relationship between AMH expression and the ratio of ERα:ERβ. The differential dose-related effect of AMH on gene expression and SMAD signalling was investigated in human granulosa-luteal cells (hGLC) from women with normal ovaries, with polycystic ovarian morphology (PCOM) and with PCOS. KGN-GC were also cultured for a prolonged period with AMH at different doses to assess the effect on cell proliferation and viability. PARTICIPANTS/MATERIALS, SETTING, METHODS: AMH protein production by cells exposed to androgens was measured by ELISA. The effect of PHTPP on the mRNA expression levels of AMH, ERα and ERβ was assessed by real-time quantitative PCR (qPCR). The influence of AMH on the relative mRNA expression levels of aromatase, AMH and its receptor AMHRII, and the FSH and LH receptor (FSHR and LHR) in control, PCOM and PCOS hGLCs was quantified by qPCR. Western blotting was used to assess changes in levels of SMAD proteins (pSMAD-1/5/8; SMAD-4; SMAD-6 and SMAD-7) after exposure of hGLCs from healthy women and women with PCOS to AMH. The ApoTox-Glo Triplex assay was used to evaluate the effect of AMH on cell viability, cytotoxicity and apoptosis. MAIN RESULTS AND THE ROLE OF CHANCE: Testosterone reduced AMH protein secreted from KGN-GC at 10-9-10-7 M (P < 0.05; P < 0.005, multiple uncorrected comparisons Fishers least squares difference), but at equivalent hyperandrogenemic levels no change was seen in AMH levels. 5α-DHT produced a significant dose-related increase in AMH protein secreted into the media (P = 0.022, ANOVA). Increasing the mRNA ratio of ERα:ERβ produced a corresponding increase in AMH mRNA expression (P = 0.015, two-way ANOVA). AMH increased mRNA levels of aromatase (P < 0.05, one-way ANOVA) and FSHR (P < 0.0001, one-way ANOVA) in hGLCs from women with PCOM, but not from normal cells or PCOS (normal n = 7, PCOM n = 5, PCOS n = 4). In contrast to hGLCs from ovulatory ovaries, in PCOS AMH reduced protein levels (cell content) of stimulatory pSMAD-1/5/8 and SMAD-4 but increased inhibitory SMAD-6 and -7 (P < 0.05, normal n = 6, PCOS n = 3). AMH at 20 and 50 ng/ml decreased KGN-GC cell proliferation but not viability after 8 days of treatment (P < 0.005, two-way ANOVA). LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: Luteinised GC from women undergoing IVF have a relatively low expression of AMH/AMHRII but advantageously continue to display responses inherent to the ovarian morphology from which they are collected. To compensate, we also utilised the KGN cell line which has been characterised to be at a developmental stage close to that of immature GC. The lack of flutamide influence on testosterone effects is not in itself sufficient evidence to conclude that the effect on AMH is mediated via conversion to oestrogen, and the effect of aromatase inhibitors or oestrogen-specific inhibitors should be tested. The effect of flutamide was tested on testosterone but not DHT. WIDER IMPLICATIONS OF THE FINDINGS: Normal folliculogenesis and ovulation are dependent on the timely reduction in AMH production from GC at the time of follicle selection. Our findings reveal for the first time that theca-derived androgens may play a role in this model but that this inhibitory action is lost at levels of androgens equivalent to those seen in PCOS. The AMH decline may either be a direct effect of androgens or an indirect one via conversion to oestradiol and acting through the upregulation of ERα, which is known to stimulate the AMH promoter. Interestingly, the ability of GCs to respond to this continually elevated AMH level appears to be reduced in cells from women with PCOS due to an adaptive alteration in the SMAD signalling pathway and lower expression of AMHRII, indicating a form of 'AMH resistance'. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the Thomas Addison Scholarship, St Georges Hospital Trust. The authors report no conflict of interest in this work and have nothing to disclose. TRIAL REGISTRATION NUMBER: N/A.
引用
- Dilaver N, Pellatt L, Jameson E, et al. The regulation and signalling of anti-Müllerian hormone in human granulosa cells: relevance to polycystic ovary syndrome. Hum Reprod. 2019. PMID: 31735954. doi:10.1093/humrep/dez214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。